LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 62

Search options

  1. Article ; Online: New immune cell engagers for cancer immunotherapy.

    Fenis, Aurore / Demaria, Olivier / Gauthier, Laurent / Vivier, Eric / Narni-Mancinelli, Emilie

    Nature reviews. Immunology

    2024  

    Abstract: There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers - antibodies engineered to redirect T cells to recognize and kill cancer cells - for the treatment of haematological malignancies. ...

    Abstract There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers - antibodies engineered to redirect T cells to recognize and kill cancer cells - for the treatment of haematological malignancies. However, the field still faces several challenges to develop agents that are consistently effective in a majority of patients and cancer types, such as optimizing drug dose, overcoming treatment resistance and improving efficacy in solid tumours. A new generation of T cell-targeted molecules was developed to tackle these issues that are potentially more effective and safer. In addition, agents designed to engage the antitumour activities of other immune cells, including natural killer cells and myeloid cells, are showing promise and have the potential to treat a broader range of cancers.
    Language English
    Publishing date 2024-01-25
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2062776-2
    ISSN 1474-1741 ; 1474-1733
    ISSN (online) 1474-1741
    ISSN 1474-1733
    DOI 10.1038/s41577-023-00982-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: ISACs take a Toll on tumors.

    Demaria, Olivier / Vivier, Eric

    Nature cancer

    2020  Volume 2, Issue 1, Page(s) 12–13

    MeSH term(s) Humans ; Neoplasms/therapy ; ST Elevation Myocardial Infarction
    Language English
    Publishing date 2020-11-30
    Publishing country England
    Document type Journal Article ; Comment
    ISSN 2662-1347
    ISSN (online) 2662-1347
    DOI 10.1038/s43018-020-00152-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Tumor-Associated Lymphocytes and Breast Cancer Survival in Black and White Women.

    Newman, Lisa A / Chen, Yalei / Martini, Rachel / Demaria, Sandra / Formenti, Silvia / Elemento, Olivier / Davis, Melissa B

    JAMA surgery

    2024  

    Language English
    Publishing date 2024-03-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2701841-6
    ISSN 2168-6262 ; 2168-6254
    ISSN (online) 2168-6262
    ISSN 2168-6254
    DOI 10.1001/jamasurg.2023.8024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Immuno-Oncology beyond TILs: Unleashing TILCs.

    Demaria, Olivier / Vivier, Eric

    Cancer cell

    2020  Volume 37, Issue 4, Page(s) 428–430

    Abstract: Innate lymphoid cells (ILCs) are detected in multiple tumor types, but their contribution to tumor immunity remains unclear. Moral et al. show that a subset of tumor ILCs (TILCs) may participate in an organ-specific immune response and can be unleashed ... ...

    Abstract Innate lymphoid cells (ILCs) are detected in multiple tumor types, but their contribution to tumor immunity remains unclear. Moral et al. show that a subset of tumor ILCs (TILCs) may participate in an organ-specific immune response and can be unleashed by PD-1 blockers to sustain tumor-specific T cell responses.
    MeSH term(s) Humans ; Immunity, Innate ; Lymphocytes ; Neoplasms ; Programmed Cell Death 1 Receptor ; T-Lymphocytes
    Chemical Substances Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2020-03-29
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 2078448-X
    ISSN 1878-3686 ; 1535-6108
    ISSN (online) 1878-3686
    ISSN 1535-6108
    DOI 10.1016/j.ccell.2020.03.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Natural killer cell engagers in cancer immunotherapy: Next generation of immuno-oncology treatments.

    Demaria, Olivier / Gauthier, Laurent / Debroas, Guilhaume / Vivier, Eric

    European journal of immunology

    2021  Volume 51, Issue 8, Page(s) 1934–1942

    Abstract: Immuno-oncology is revolutionizing the treatment of cancers, by inducing the recognition and elimination of tumor cells by the immune system. Recent advances have focused on generating or unleashing tumor antigen-specific T-cell responses, leading to ... ...

    Abstract Immuno-oncology is revolutionizing the treatment of cancers, by inducing the recognition and elimination of tumor cells by the immune system. Recent advances have focused on generating or unleashing tumor antigen-specific T-cell responses, leading to alternative treatment paradigms for many cancers. Despite these successes, the clinical benefit has been limited to a subset of patients and certain tumor types, highlighting the need for alternative strategies. One innovative approach is to broaden and amplify antitumoral immune responses by targeting innate immunity. Particularly, the aim has been to develop new antibody formats capable of stimulating the antitumor activity of innate immune cells, boosting not only their direct role in tumor elimination, but also their function in eliciting multicellular immune responses ultimately resulting in long-lasting tumor control by adaptive immunity. This review covers the development of a new class of synthetic molecules, natural killer cell engagers (NKCEs), which are built from fragments of monoclonal antibodies (mAbs) and are designed to harness the immune functions of NK cells in cancer. As currently shown in preclinical studies and clinical trials, NKCEs are promising candidates for the next generation of tumor immunotherapies.
    MeSH term(s) Animals ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Humans ; Immunotherapy/methods ; Immunotherapy/trends ; Killer Cells, Natural/immunology ; Medical Oncology/trends ; Neoplasms/drug therapy ; Neoplasms/immunology
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents, Immunological
    Language English
    Publishing date 2021-06-18
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 120108-6
    ISSN 1521-4141 ; 0014-2980
    ISSN (online) 1521-4141
    ISSN 0014-2980
    DOI 10.1002/eji.202048953
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19

    Demaria, Olivier / Carvelli, Julien / Batista, Luciana

    Cellular & Molecular Immunology

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #655049
    Database COVID19

    Kategorien

  7. Article ; Online: Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea.

    Mylonas, Alessio / Hawerkamp, Heike C / Wang, Yichen / Chen, Jiaqi / Messina, Francesco / Demaria, Olivier / Meller, Stephan / Homey, Bernhard / Di Domizio, Jeremy / Mazzolai, Lucia / Hovnanian, Alain / Gilliet, Michel / Conrad, Curdin

    JCI insight

    2023  Volume 8, Issue 4

    Abstract: Rosacea is a common chronic inflammatory skin disease with a fluctuating course of excessive inflammation and apparent neovascularization. Microbial dysbiosis with a high density of Bacillus oleronius and increased activity of kallikrein 5, which cleaves ...

    Abstract Rosacea is a common chronic inflammatory skin disease with a fluctuating course of excessive inflammation and apparent neovascularization. Microbial dysbiosis with a high density of Bacillus oleronius and increased activity of kallikrein 5, which cleaves cathelicidin antimicrobial peptide, are key pathogenic triggers in rosacea. However, how these events are linked to the disease remains unknown. Here, we show that type I IFNs produced by plasmacytoid DCs represent the pivotal link between dysbiosis, the aberrant immune response, and neovascularization. Compared with other commensal bacteria, B. oleronius is highly susceptible and preferentially killed by cathelicidin antimicrobial peptides, leading to enhanced generation of complexes with bacterial DNA. These bacterial DNA complexes but not DNA complexes derived from host cells are required for cathelicidin-induced activation of plasmacytoid DCs and type I IFN production. Moreover, kallikrein 5 cleaves cathelicidin into peptides with heightened DNA binding and type I IFN-inducing capacities. In turn, excessive type I IFN expression drives neoangiogenesis via IL-22 induction and upregulation of the IL-22 receptor on endothelial cells. These findings unravel a potentially novel pathomechanism that directly links hallmarks of rosacea to the killing of dysbiotic commensal bacteria with induction of a pathogenic type I IFN-driven and IL-22-mediated angiogenesis.
    MeSH term(s) Humans ; Bacteria ; Cathelicidins ; DNA, Bacterial ; Dysbiosis/microbiology ; Endothelial Cells/metabolism ; Inflammation/metabolism ; Inflammation/microbiology ; Kallikreins ; Rosacea/metabolism ; Rosacea/microbiology ; Rosacea/pathology ; Interferon Type I/metabolism ; Microbiota/physiology ; Bacillus/metabolism ; Skin/metabolism ; Skin/microbiology ; Skin/pathology ; Neovascularization, Pathologic/microbiology
    Chemical Substances Cathelicidins ; DNA, Bacterial ; Kallikreins (EC 3.4.21.-) ; Interferon Type I
    Language English
    Publishing date 2023-02-22
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2379-3708
    ISSN (online) 2379-3708
    DOI 10.1172/jci.insight.151846
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Publisher Correction: Harnessing innate immunity in cancer therapy.

    Demaria, Olivier / Cornen, Stéphanie / Daëron, Marc / Morel, Yannis / Medzhitov, Ruslan / Vivier, Eric

    Nature

    2019  Volume 576, Issue 7785, Page(s) E3

    Abstract: An Amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    Abstract An Amendment to this paper has been published and can be accessed via a link at the top of the paper.
    Language English
    Publishing date 2019-11-16
    Publishing country England
    Document type Journal Article ; Published Erratum
    ZDB-ID 120714-3
    ISSN 1476-4687 ; 0028-0836
    ISSN (online) 1476-4687
    ISSN 0028-0836
    DOI 10.1038/s41586-019-1758-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Type I IFNs link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea

    Alessio Mylonas / Heike C. Hawerkamp / Yichen Wang / Jiaqi Chen / Francesco Messina / Olivier Demaria / Stephan Meller / Bernhard Homey / Jeremy Di Domizio / Lucia Mazzolai / Alain Hovnanian / Michel Gilliet / Curdin Conrad

    JCI Insight, Vol 8, Iss

    2023  Volume 4

    Abstract: Rosacea is a common chronic inflammatory skin disease with a fluctuating course of excessive inflammation and apparent neovascularization. Microbial dysbiosis with a high density of Bacillus oleronius and increased activity of kallikrein 5, which cleaves ...

    Abstract Rosacea is a common chronic inflammatory skin disease with a fluctuating course of excessive inflammation and apparent neovascularization. Microbial dysbiosis with a high density of Bacillus oleronius and increased activity of kallikrein 5, which cleaves cathelicidin antimicrobial peptide, are key pathogenic triggers in rosacea. However, how these events are linked to the disease remains unknown. Here, we show that type I IFNs produced by plasmacytoid DCs represent the pivotal link between dysbiosis, the aberrant immune response, and neovascularization. Compared with other commensal bacteria, B. oleronius is highly susceptible and preferentially killed by cathelicidin antimicrobial peptides, leading to enhanced generation of complexes with bacterial DNA. These bacterial DNA complexes but not DNA complexes derived from host cells are required for cathelicidin-induced activation of plasmacytoid DCs and type I IFN production. Moreover, kallikrein 5 cleaves cathelicidin into peptides with heightened DNA binding and type I IFN–inducing capacities. In turn, excessive type I IFN expression drives neoangiogenesis via IL-22 induction and upregulation of the IL-22 receptor on endothelial cells. These findings unravel a potentially novel pathomechanism that directly links hallmarks of rosacea to the killing of dysbiotic commensal bacteria with induction of a pathogenic type I IFN–driven and IL-22–mediated angiogenesis.
    Keywords Dermatology ; Inflammation ; Medicine ; R
    Language English
    Publishing date 2023-02-01T00:00:00Z
    Publisher American Society for Clinical investigation
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Harnessing innate immunity in cancer therapy.

    Demaria, Olivier / Cornen, Stéphanie / Daëron, Marc / Morel, Yannis / Medzhitov, Ruslan / Vivier, Eric

    Nature

    2019  Volume 574, Issue 7776, Page(s) 45–56

    Abstract: New therapies that promote antitumour immunity have been recently developed. Most of these immunomodulatory approaches have focused on enhancing T-cell responses, either by targeting inhibitory pathways with immune checkpoint inhibitors, or by targeting ... ...

    Abstract New therapies that promote antitumour immunity have been recently developed. Most of these immunomodulatory approaches have focused on enhancing T-cell responses, either by targeting inhibitory pathways with immune checkpoint inhibitors, or by targeting activating pathways, as with chimeric antigen receptor T cells or bispecific antibodies. Although these therapies have led to unprecedented successes, only a minority of patients with cancer benefit from these treatments, highlighting the need to identify new cells and molecules that could be exploited in the next generation of immunotherapy. Given the crucial role of innate immune responses in immunity, harnessing these responses opens up new possibilities for long-lasting, multilayered tumour control.
    MeSH term(s) Animals ; Humans ; Immunity, Innate/drug effects ; Immunity, Innate/immunology ; Immunotherapy/methods ; Immunotherapy/trends ; Neoplasms/drug therapy ; Neoplasms/immunology ; Neoplasms/therapy ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology
    Language English
    Publishing date 2019-10-02
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 120714-3
    ISSN 1476-4687 ; 0028-0836
    ISSN (online) 1476-4687
    ISSN 0028-0836
    DOI 10.1038/s41586-019-1593-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top